nodes	percent_of_prediction	percent_of_DWPC	metapath
Lapatinib—CYP3A5—Ifosfamide—testicular cancer	0.0697	0.152	CbGbCtD
Lapatinib—CYP2C8—Ifosfamide—testicular cancer	0.067	0.147	CbGbCtD
Lapatinib—CYP2C19—Ifosfamide—testicular cancer	0.0562	0.123	CbGbCtD
Lapatinib—ABCB1—Dactinomycin—testicular cancer	0.0384	0.084	CbGbCtD
Lapatinib—CYP3A5—Etoposide—testicular cancer	0.0333	0.0729	CbGbCtD
Lapatinib—CYP2C8—Etoposide—testicular cancer	0.032	0.0701	CbGbCtD
Lapatinib—CYP3A4—Ifosfamide—testicular cancer	0.0272	0.0595	CbGbCtD
Lapatinib—ABCB1—Vinblastine—testicular cancer	0.024	0.0526	CbGbCtD
Lapatinib—ABCB1—Cisplatin—testicular cancer	0.0221	0.0483	CbGbCtD
Lapatinib—ABCB1—Etoposide—testicular cancer	0.0217	0.0474	CbGbCtD
Lapatinib—ABCB1—Doxorubicin—testicular cancer	0.0148	0.0324	CbGbCtD
Lapatinib—CYP3A4—Vinblastine—testicular cancer	0.0144	0.0315	CbGbCtD
Lapatinib—ABCB1—Methotrexate—testicular cancer	0.0143	0.0313	CbGbCtD
Lapatinib—CYP3A4—Etoposide—testicular cancer	0.013	0.0284	CbGbCtD
Lapatinib—Gefitinib—STK10—testicular cancer	0.0122	1	CrCbGaD
Lapatinib—TAP1—seminal vesicle—testicular cancer	0.00907	0.0827	CbGeAlD
Lapatinib—CYP3A4—Doxorubicin—testicular cancer	0.00885	0.0194	CbGbCtD
Lapatinib—PIK3C2B—seminal vesicle—testicular cancer	0.00851	0.0776	CbGeAlD
Lapatinib—ERBB2—embryo—testicular cancer	0.00705	0.0643	CbGeAlD
Lapatinib—ERBB4—embryo—testicular cancer	0.00705	0.0643	CbGeAlD
Lapatinib—PI4KB—seminal vesicle—testicular cancer	0.0062	0.0565	CbGeAlD
Lapatinib—TAP1—female gonad—testicular cancer	0.00532	0.0485	CbGeAlD
Lapatinib—PIK3C2B—female gonad—testicular cancer	0.005	0.0456	CbGeAlD
Lapatinib—ERBB2—gonad—testicular cancer	0.00478	0.0436	CbGeAlD
Lapatinib—TAP1—testis—testicular cancer	0.00472	0.0431	CbGeAlD
Lapatinib—PI4KB—gonad—testicular cancer	0.00448	0.0409	CbGeAlD
Lapatinib—PIK3C2B—testis—testicular cancer	0.00443	0.0404	CbGeAlD
Lapatinib—ERBB2—female gonad—testicular cancer	0.00389	0.0354	CbGeAlD
Lapatinib—PI4KB—female gonad—testicular cancer	0.00364	0.0332	CbGeAlD
Lapatinib—ERBB2—testis—testicular cancer	0.00345	0.0314	CbGeAlD
Lapatinib—ERBB4—testis—testicular cancer	0.00345	0.0314	CbGeAlD
Lapatinib—TAP1—lymph node—testicular cancer	0.00342	0.0312	CbGeAlD
Lapatinib—EGFR—female gonad—testicular cancer	0.0033	0.0301	CbGeAlD
Lapatinib—PI4KB—testis—testicular cancer	0.00323	0.0294	CbGeAlD
Lapatinib—PIK3C2B—lymph node—testicular cancer	0.00321	0.0293	CbGeAlD
Lapatinib—EGFR—testis—testicular cancer	0.00292	0.0267	CbGeAlD
Lapatinib—ERBB2—lymph node—testicular cancer	0.0025	0.0228	CbGeAlD
Lapatinib—PIK3C2B—Vindesine—Vinblastine—testicular cancer	0.00235	0.26	CbGdCrCtD
Lapatinib—PI4KB—lymph node—testicular cancer	0.00234	0.0213	CbGeAlD
Lapatinib—EGFR—lymph node—testicular cancer	0.00212	0.0193	CbGeAlD
Lapatinib—PIK3C2B—Vinorelbine—Vinblastine—testicular cancer	0.00148	0.164	CbGdCrCtD
Lapatinib—PIK3C2B—Podofilox—Etoposide—testicular cancer	0.00148	0.164	CbGdCrCtD
Lapatinib—PIK3C2B—Vincristine—Vinblastine—testicular cancer	0.00127	0.14	CbGdCrCtD
Lapatinib—ERBB2—Podofilox—Etoposide—testicular cancer	0.00122	0.135	CbGdCrCtD
Lapatinib—CYP3A5—female gonad—testicular cancer	0.000953	0.00869	CbGeAlD
Lapatinib—CYP2C8—testis—testicular cancer	0.000937	0.00854	CbGeAlD
Lapatinib—ABCB1—embryo—testicular cancer	0.000918	0.00837	CbGeAlD
Lapatinib—ABCB1—seminal vesicle—testicular cancer	0.000862	0.00786	CbGeAlD
Lapatinib—ERBB2—Doxorubicin—Epirubicin—testicular cancer	0.000637	0.0705	CbGdCrCtD
Lapatinib—ABCB1—gonad—testicular cancer	0.000623	0.00568	CbGeAlD
Lapatinib—ERBB2—B Cell Activation—KITLG—testicular cancer	0.000606	0.00402	CbGpPWpGaD
Lapatinib—ERBB4—B Cell Activation—KITLG—testicular cancer	0.000597	0.00396	CbGpPWpGaD
Lapatinib—ERBB2—Epirubicin—Doxorubicin—testicular cancer	0.00059	0.0652	CbGdCrCtD
Lapatinib—ERBB2—Signaling by SCF-KIT—FGFR3—testicular cancer	0.000584	0.00387	CbGpPWpGaD
Lapatinib—ERBB2—NGF signalling via TRKA from the plasma membrane—KITLG—testicular cancer	0.00058	0.00385	CbGpPWpGaD
Lapatinib—ERBB4—Signaling by SCF-KIT—FGFR3—testicular cancer	0.000575	0.00381	CbGpPWpGaD
Lapatinib—ERBB4—NGF signalling via TRKA from the plasma membrane—KITLG—testicular cancer	0.000572	0.00379	CbGpPWpGaD
Lapatinib—EGFR—Constitutive PI3K/AKT Signaling in Cancer—KITLG—testicular cancer	0.000564	0.00374	CbGpPWpGaD
Lapatinib—ERBB2—Downstream signaling of activated FGFR—FGFR3—testicular cancer	0.000559	0.0037	CbGpPWpGaD
Lapatinib—ERBB4—Downstream signaling of activated FGFR—FGFR3—testicular cancer	0.00055	0.00365	CbGpPWpGaD
Lapatinib—EGFR—Downstream signaling events of B Cell Receptor (BCR)—BCL10—testicular cancer	0.00055	0.00365	CbGpPWpGaD
Lapatinib—ERBB2—Signaling by ERBB4—FGFR3—testicular cancer	0.00055	0.00365	CbGpPWpGaD
Lapatinib—ERBB4—Signaling by ERBB4—FGFR3—testicular cancer	0.000542	0.00359	CbGpPWpGaD
Lapatinib—ERBB2—Signaling by SCF-KIT—KIT—testicular cancer	0.000536	0.00355	CbGpPWpGaD
Lapatinib—ERBB4—Signaling by SCF-KIT—KIT—testicular cancer	0.000528	0.0035	CbGpPWpGaD
Lapatinib—ERBB2—Downstream signal transduction—FGFR3—testicular cancer	0.000525	0.00348	CbGpPWpGaD
Lapatinib—EGFR—Fc epsilon receptor (FCERI) signaling—BCL10—testicular cancer	0.000525	0.00348	CbGpPWpGaD
Lapatinib—ERBB2—Signaling by FGFR—FGFR3—testicular cancer	0.000523	0.00346	CbGpPWpGaD
Lapatinib—ERBB2—Signaling by ERBB2—FGFR3—testicular cancer	0.00052	0.00345	CbGpPWpGaD
Lapatinib—ERBB2—DAP12 signaling—FGFR3—testicular cancer	0.000518	0.00343	CbGpPWpGaD
Lapatinib—ERBB4—Downstream signal transduction—FGFR3—testicular cancer	0.000517	0.00343	CbGpPWpGaD
Lapatinib—ERBB4—Signaling by FGFR—FGFR3—testicular cancer	0.000515	0.00341	CbGpPWpGaD
Lapatinib—ERBB2—Downstream signaling of activated FGFR—KIT—testicular cancer	0.000513	0.0034	CbGpPWpGaD
Lapatinib—ERBB4—Signaling by ERBB2—FGFR3—testicular cancer	0.000512	0.0034	CbGpPWpGaD
Lapatinib—ERBB2—Downstream signaling events of B Cell Receptor (BCR)—FGFR3—testicular cancer	0.00051	0.00338	CbGpPWpGaD
Lapatinib—ERBB4—DAP12 signaling—FGFR3—testicular cancer	0.00051	0.00338	CbGpPWpGaD
Lapatinib—EGFR—PI-3K cascade—KITLG—testicular cancer	0.000508	0.00337	CbGpPWpGaD
Lapatinib—ABCB1—female gonad—testicular cancer	0.000506	0.00462	CbGeAlD
Lapatinib—ERBB4—Downstream signaling of activated FGFR—KIT—testicular cancer	0.000505	0.00335	CbGpPWpGaD
Lapatinib—ERBB2—Signaling by ERBB4—KIT—testicular cancer	0.000505	0.00335	CbGpPWpGaD
Lapatinib—ERBB4—Downstream signaling events of B Cell Receptor (BCR)—FGFR3—testicular cancer	0.000502	0.00333	CbGpPWpGaD
Lapatinib—ERBB4—Signaling by ERBB4—KIT—testicular cancer	0.000497	0.0033	CbGpPWpGaD
Lapatinib—EGFR—PI3K/AKT activation—KITLG—testicular cancer	0.000496	0.00329	CbGpPWpGaD
Lapatinib—EGFR—GAB1 signalosome—KITLG—testicular cancer	0.000492	0.00326	CbGpPWpGaD
Lapatinib—ERBB2—Fc epsilon receptor (FCERI) signaling—FGFR3—testicular cancer	0.000487	0.00323	CbGpPWpGaD
Lapatinib—ERBB2—DAP12 interactions—FGFR3—testicular cancer	0.000487	0.00323	CbGpPWpGaD
Lapatinib—ERBB2—Signaling by FGFR in disease—FGFR3—testicular cancer	0.000487	0.00323	CbGpPWpGaD
Lapatinib—EGFR—B Cell Activation—BCL10—testicular cancer	0.000486	0.00322	CbGpPWpGaD
Lapatinib—TAP1—Adaptive Immune System—FGFR3—testicular cancer	0.000483	0.0032	CbGpPWpGaD
Lapatinib—ERBB2—Signaling by EGFR—FGFR3—testicular cancer	0.000483	0.0032	CbGpPWpGaD
Lapatinib—ERBB2—Downstream signal transduction—KIT—testicular cancer	0.000482	0.0032	CbGpPWpGaD
Lapatinib—EGFR—Role of LAT2/NTAL/LAB on calcium mobilization—KITLG—testicular cancer	0.000481	0.00319	CbGpPWpGaD
Lapatinib—ERBB2—Signaling by FGFR—KIT—testicular cancer	0.00048	0.00318	CbGpPWpGaD
Lapatinib—ERBB4—Fc epsilon receptor (FCERI) signaling—FGFR3—testicular cancer	0.00048	0.00318	CbGpPWpGaD
Lapatinib—ERBB4—DAP12 interactions—FGFR3—testicular cancer	0.00048	0.00318	CbGpPWpGaD
Lapatinib—ERBB4—Signaling by FGFR in disease—FGFR3—testicular cancer	0.00048	0.00318	CbGpPWpGaD
Lapatinib—ERBB2—Signaling by EGFR in Cancer—FGFR3—testicular cancer	0.000478	0.00317	CbGpPWpGaD
Lapatinib—ERBB2—Signaling by ERBB2—KIT—testicular cancer	0.000478	0.00316	CbGpPWpGaD
Lapatinib—ERBB2—Signaling by PDGF—FGFR3—testicular cancer	0.000476	0.00316	CbGpPWpGaD
Lapatinib—ERBB4—Signaling by EGFR—FGFR3—testicular cancer	0.000475	0.00315	CbGpPWpGaD
Lapatinib—ERBB2—DAP12 signaling—KIT—testicular cancer	0.000475	0.00315	CbGpPWpGaD
Lapatinib—ERBB4—Downstream signal transduction—KIT—testicular cancer	0.000475	0.00315	CbGpPWpGaD
Lapatinib—ERBB4—Signaling by FGFR—KIT—testicular cancer	0.000473	0.00313	CbGpPWpGaD
Lapatinib—ERBB4—Signaling by EGFR in Cancer—FGFR3—testicular cancer	0.000471	0.00312	CbGpPWpGaD
Lapatinib—ERBB4—Signaling by ERBB2—KIT—testicular cancer	0.00047	0.00312	CbGpPWpGaD
Lapatinib—ERBB4—Signaling by PDGF—FGFR3—testicular cancer	0.000469	0.00311	CbGpPWpGaD
Lapatinib—ERBB2—Downstream signaling events of B Cell Receptor (BCR)—KIT—testicular cancer	0.000468	0.0031	CbGpPWpGaD
Lapatinib—ERBB4—DAP12 signaling—KIT—testicular cancer	0.000468	0.0031	CbGpPWpGaD
Lapatinib—ERBB4—Downstream signaling events of B Cell Receptor (BCR)—KIT—testicular cancer	0.000461	0.00306	CbGpPWpGaD
Lapatinib—Immune system disorder—Etoposide—testicular cancer	0.000455	0.00174	CcSEcCtD
Lapatinib—Mediastinal disorder—Etoposide—testicular cancer	0.000454	0.00174	CcSEcCtD
Lapatinib—Anaphylactic shock—Ifosfamide—testicular cancer	0.000453	0.00173	CcSEcCtD
Lapatinib—ERBB2—B Cell Activation—FGFR3—testicular cancer	0.000451	0.00299	CbGpPWpGaD
Lapatinib—Musculoskeletal discomfort—Dactinomycin—testicular cancer	0.000451	0.00172	CcSEcCtD
Lapatinib—Asthenia—Vinblastine—testicular cancer	0.00045	0.00172	CcSEcCtD
Lapatinib—Infection—Ifosfamide—testicular cancer	0.00045	0.00172	CcSEcCtD
Lapatinib—ABCB1—testis—testicular cancer	0.000449	0.0041	CbGeAlD
Lapatinib—ERBB2—DAP12 interactions—KIT—testicular cancer	0.000447	0.00296	CbGpPWpGaD
Lapatinib—ERBB2—Signaling by FGFR in disease—KIT—testicular cancer	0.000447	0.00296	CbGpPWpGaD
Lapatinib—ERBB2—Fc epsilon receptor (FCERI) signaling—KIT—testicular cancer	0.000447	0.00296	CbGpPWpGaD
Lapatinib—ERBB2—Signaling by NGF—KITLG—testicular cancer	0.000446	0.00296	CbGpPWpGaD
Lapatinib—Alopecia—Etoposide—testicular cancer	0.000445	0.0017	CcSEcCtD
Lapatinib—Nervous system disorder—Ifosfamide—testicular cancer	0.000444	0.0017	CcSEcCtD
Lapatinib—TAP1—Adaptive Immune System—KIT—testicular cancer	0.000444	0.00294	CbGpPWpGaD
Lapatinib—ERBB4—B Cell Activation—FGFR3—testicular cancer	0.000444	0.00294	CbGpPWpGaD
Lapatinib—EGFR—Integrated Pancreatic Cancer Pathway—HPGDS—testicular cancer	0.000443	0.00294	CbGpPWpGaD
Lapatinib—ERBB2—Signaling by EGFR—KIT—testicular cancer	0.000443	0.00294	CbGpPWpGaD
Lapatinib—Anaemia—Cisplatin—testicular cancer	0.000442	0.00169	CcSEcCtD
Lapatinib—Renal failure acute—Epirubicin—testicular cancer	0.000442	0.00169	CcSEcCtD
Lapatinib—ERBB4—DAP12 interactions—KIT—testicular cancer	0.00044	0.00292	CbGpPWpGaD
Lapatinib—ERBB4—Fc epsilon receptor (FCERI) signaling—KIT—testicular cancer	0.00044	0.00292	CbGpPWpGaD
Lapatinib—ERBB4—Signaling by FGFR in disease—KIT—testicular cancer	0.00044	0.00292	CbGpPWpGaD
Lapatinib—Skin disorder—Ifosfamide—testicular cancer	0.00044	0.00168	CcSEcCtD
Lapatinib—ERBB4—Signaling by NGF—KITLG—testicular cancer	0.00044	0.00291	CbGpPWpGaD
Lapatinib—ERBB2—Signaling by EGFR in Cancer—KIT—testicular cancer	0.000439	0.00291	CbGpPWpGaD
Lapatinib—ERBB2—Signaling by PDGF—KIT—testicular cancer	0.000437	0.0029	CbGpPWpGaD
Lapatinib—ERBB4—Signaling by EGFR—KIT—testicular cancer	0.000436	0.00289	CbGpPWpGaD
Lapatinib—Hot flush—Epirubicin—testicular cancer	0.000436	0.00167	CcSEcCtD
Lapatinib—Vomiting—Chlorambucil—testicular cancer	0.000436	0.00167	CcSEcCtD
Lapatinib—Menopausal symptoms—Epirubicin—testicular cancer	0.000433	0.00165	CcSEcCtD
Lapatinib—ERBB4—Signaling by EGFR in Cancer—KIT—testicular cancer	0.000433	0.00287	CbGpPWpGaD
Lapatinib—EGFR—LPA receptor mediated events—MMP2—testicular cancer	0.000432	0.00286	CbGpPWpGaD
Lapatinib—Anorexia—Ifosfamide—testicular cancer	0.000432	0.00165	CcSEcCtD
Lapatinib—ERBB2—NGF signalling via TRKA from the plasma membrane—FGFR3—testicular cancer	0.000431	0.00286	CbGpPWpGaD
Lapatinib—ERBB4—Signaling by PDGF—KIT—testicular cancer	0.000431	0.00285	CbGpPWpGaD
Lapatinib—Decreased appetite—Dactinomycin—testicular cancer	0.00043	0.00164	CcSEcCtD
Lapatinib—Diarrhoea—Vinblastine—testicular cancer	0.00043	0.00164	CcSEcCtD
Lapatinib—Leukopenia—Cisplatin—testicular cancer	0.000429	0.00164	CcSEcCtD
Lapatinib—Fatigue—Dactinomycin—testicular cancer	0.000426	0.00163	CcSEcCtD
Lapatinib—ERBB4—NGF signalling via TRKA from the plasma membrane—FGFR3—testicular cancer	0.000425	0.00282	CbGpPWpGaD
Lapatinib—Back pain—Etoposide—testicular cancer	0.000424	0.00162	CcSEcCtD
Lapatinib—ERBB2—Innate Immune System—BCL10—testicular cancer	0.000422	0.0028	CbGpPWpGaD
Lapatinib—EGFR—AGE/RAGE pathway—MMP2—testicular cancer	0.000422	0.00279	CbGpPWpGaD
Lapatinib—EGFR—Constitutive PI3K/AKT Signaling in Cancer—FGFR3—testicular cancer	0.000419	0.00278	CbGpPWpGaD
Lapatinib—PIK3C2B—Metabolism—HPGDS—testicular cancer	0.000419	0.00278	CbGpPWpGaD
Lapatinib—Cardiac failure—Epirubicin—testicular cancer	0.000418	0.0016	CcSEcCtD
Lapatinib—ERBB4—Innate Immune System—BCL10—testicular cancer	0.000416	0.00276	CbGpPWpGaD
Lapatinib—ERBB2—B Cell Activation—KIT—testicular cancer	0.000414	0.00274	CbGpPWpGaD
Lapatinib—Musculoskeletal discomfort—Ifosfamide—testicular cancer	0.000413	0.00158	CcSEcCtD
Lapatinib—Renal failure acute—Doxorubicin—testicular cancer	0.000409	0.00156	CcSEcCtD
Lapatinib—Pain in extremity—Epirubicin—testicular cancer	0.000408	0.00156	CcSEcCtD
Lapatinib—Myalgia—Cisplatin—testicular cancer	0.000408	0.00156	CcSEcCtD
Lapatinib—ERBB4—B Cell Activation—KIT—testicular cancer	0.000408	0.0027	CbGpPWpGaD
Lapatinib—Nausea—Chlorambucil—testicular cancer	0.000407	0.00156	CcSEcCtD
Lapatinib—Anaemia—Etoposide—testicular cancer	0.000405	0.00155	CcSEcCtD
Lapatinib—ERBB2—Adaptive Immune System—BCL10—testicular cancer	0.000405	0.00269	CbGpPWpGaD
Lapatinib—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—testicular cancer	0.000405	0.00155	CcSEcCtD
Lapatinib—PI4KB—Metabolism—HPGDS—testicular cancer	0.000404	0.00268	CbGpPWpGaD
Lapatinib—Gastrointestinal pain—Dactinomycin—testicular cancer	0.000404	0.00155	CcSEcCtD
Lapatinib—Dyspnoea—Ifosfamide—testicular cancer	0.000404	0.00155	CcSEcCtD
Lapatinib—Hot flush—Doxorubicin—testicular cancer	0.000404	0.00154	CcSEcCtD
Lapatinib—Menopausal symptoms—Doxorubicin—testicular cancer	0.0004	0.00153	CcSEcCtD
Lapatinib—ERBB4—Adaptive Immune System—BCL10—testicular cancer	0.000399	0.00265	CbGpPWpGaD
Lapatinib—Vomiting—Vinblastine—testicular cancer	0.000399	0.00153	CcSEcCtD
Lapatinib—ERBB2—NGF signalling via TRKA from the plasma membrane—KIT—testicular cancer	0.000396	0.00262	CbGpPWpGaD
Lapatinib—TAP1—Immune System—KITLG—testicular cancer	0.000395	0.00262	CbGpPWpGaD
Lapatinib—Decreased appetite—Ifosfamide—testicular cancer	0.000394	0.00151	CcSEcCtD
Lapatinib—Headache—Vinblastine—testicular cancer	0.000393	0.0015	CcSEcCtD
Lapatinib—Leukopenia—Etoposide—testicular cancer	0.000393	0.0015	CcSEcCtD
Lapatinib—Gastrointestinal disorder—Ifosfamide—testicular cancer	0.000391	0.0015	CcSEcCtD
Lapatinib—Abdominal pain—Dactinomycin—testicular cancer	0.000391	0.0015	CcSEcCtD
Lapatinib—Fatigue—Ifosfamide—testicular cancer	0.000391	0.00149	CcSEcCtD
Lapatinib—Anaphylactic shock—Cisplatin—testicular cancer	0.000391	0.00149	CcSEcCtD
Lapatinib—Hypersensitivity—Bleomycin—testicular cancer	0.000391	0.00149	CcSEcCtD
Lapatinib—ERBB4—NGF signalling via TRKA from the plasma membrane—KIT—testicular cancer	0.00039	0.00258	CbGpPWpGaD
Lapatinib—EGFR—Integrated Breast Cancer Pathway—STK11—testicular cancer	0.000389	0.00258	CbGpPWpGaD
Lapatinib—Infection—Cisplatin—testicular cancer	0.000388	0.00148	CcSEcCtD
Lapatinib—Constipation—Ifosfamide—testicular cancer	0.000388	0.00148	CcSEcCtD
Lapatinib—Cardiac failure—Doxorubicin—testicular cancer	0.000387	0.00148	CcSEcCtD
Lapatinib—EGFR—Constitutive PI3K/AKT Signaling in Cancer—KIT—testicular cancer	0.000385	0.00255	CbGpPWpGaD
Lapatinib—Nervous system disorder—Cisplatin—testicular cancer	0.000383	0.00147	CcSEcCtD
Lapatinib—Cough—Etoposide—testicular cancer	0.000383	0.00146	CcSEcCtD
Lapatinib—Asthenia—Bleomycin—testicular cancer	0.00038	0.00146	CcSEcCtD
Lapatinib—EGFR—Signaling by SCF-KIT—KITLG—testicular cancer	0.00038	0.00252	CbGpPWpGaD
Lapatinib—Dehydration—Epirubicin—testicular cancer	0.00038	0.00145	CcSEcCtD
Lapatinib—Skin disorder—Cisplatin—testicular cancer	0.00038	0.00145	CcSEcCtD
Lapatinib—EGFR—PI-3K cascade—FGFR3—testicular cancer	0.000378	0.0025	CbGpPWpGaD
Lapatinib—Pain in extremity—Doxorubicin—testicular cancer	0.000378	0.00144	CcSEcCtD
Lapatinib—Pruritus—Bleomycin—testicular cancer	0.000375	0.00143	CcSEcCtD
Lapatinib—Dry skin—Epirubicin—testicular cancer	0.000374	0.00143	CcSEcCtD
Lapatinib—Nausea—Vinblastine—testicular cancer	0.000373	0.00143	CcSEcCtD
Lapatinib—Anorexia—Cisplatin—testicular cancer	0.000372	0.00142	CcSEcCtD
Lapatinib—Unspecified disorder of skin and subcutaneous tissue—Etoposide—testicular cancer	0.000371	0.00142	CcSEcCtD
Lapatinib—Gastrointestinal pain—Ifosfamide—testicular cancer	0.000371	0.00142	CcSEcCtD
Lapatinib—EGFR—PI3K/AKT activation—FGFR3—testicular cancer	0.000369	0.00244	CbGpPWpGaD
Lapatinib—EGFR—GAB1 signalosome—FGFR3—testicular cancer	0.000366	0.00242	CbGpPWpGaD
Lapatinib—Hypersensitivity—Dactinomycin—testicular cancer	0.000364	0.00139	CcSEcCtD
Lapatinib—EGFR—Downstream signaling of activated FGFR—KITLG—testicular cancer	0.000364	0.00241	CbGpPWpGaD
Lapatinib—Alanine aminotransferase increased—Epirubicin—testicular cancer	0.00036	0.00138	CcSEcCtD
Lapatinib—Abdominal pain—Ifosfamide—testicular cancer	0.000358	0.00137	CcSEcCtD
Lapatinib—Anaphylactic shock—Etoposide—testicular cancer	0.000358	0.00137	CcSEcCtD
Lapatinib—EGFR—Signaling by ERBB4—KITLG—testicular cancer	0.000358	0.00237	CbGpPWpGaD
Lapatinib—EGFR—Role of LAT2/NTAL/LAB on calcium mobilization—FGFR3—testicular cancer	0.000357	0.00237	CbGpPWpGaD
Lapatinib—Musculoskeletal discomfort—Cisplatin—testicular cancer	0.000356	0.00136	CcSEcCtD
Lapatinib—Infection—Etoposide—testicular cancer	0.000356	0.00136	CcSEcCtD
Lapatinib—Asthenia—Dactinomycin—testicular cancer	0.000355	0.00136	CcSEcCtD
Lapatinib—Neutropenia—Methotrexate—testicular cancer	0.000353	0.00135	CcSEcCtD
Lapatinib—Dehydration—Doxorubicin—testicular cancer	0.000351	0.00134	CcSEcCtD
Lapatinib—Dyspnoea—Cisplatin—testicular cancer	0.000348	0.00133	CcSEcCtD
Lapatinib—Skin disorder—Etoposide—testicular cancer	0.000348	0.00133	CcSEcCtD
Lapatinib—EGFR—PI-3K cascade—KIT—testicular cancer	0.000347	0.0023	CbGpPWpGaD
Lapatinib—Dry skin—Doxorubicin—testicular cancer	0.000346	0.00132	CcSEcCtD
Lapatinib—EGFR—Downstream signal transduction—KITLG—testicular cancer	0.000342	0.00226	CbGpPWpGaD
Lapatinib—Anorexia—Etoposide—testicular cancer	0.000341	0.0013	CcSEcCtD
Lapatinib—EGFR—Signaling by FGFR—KITLG—testicular cancer	0.00034	0.00225	CbGpPWpGaD
Lapatinib—Decreased appetite—Cisplatin—testicular cancer	0.00034	0.0013	CcSEcCtD
Lapatinib—EGFR—PI3K/AKT activation—KIT—testicular cancer	0.000339	0.00224	CbGpPWpGaD
Lapatinib—Diarrhoea—Dactinomycin—testicular cancer	0.000338	0.00129	CcSEcCtD
Lapatinib—EGFR—Signaling by ERBB2—KITLG—testicular cancer	0.000338	0.00224	CbGpPWpGaD
Lapatinib—Pneumonia—Methotrexate—testicular cancer	0.000338	0.00129	CcSEcCtD
Lapatinib—Gastrointestinal disorder—Cisplatin—testicular cancer	0.000337	0.00129	CcSEcCtD
Lapatinib—Vomiting—Bleomycin—testicular cancer	0.000337	0.00129	CcSEcCtD
Lapatinib—EGFR—DAP12 signaling—KITLG—testicular cancer	0.000337	0.00223	CbGpPWpGaD
Lapatinib—Infestation—Methotrexate—testicular cancer	0.000336	0.00129	CcSEcCtD
Lapatinib—Infestation NOS—Methotrexate—testicular cancer	0.000336	0.00129	CcSEcCtD
Lapatinib—EGFR—GAB1 signalosome—KIT—testicular cancer	0.000336	0.00223	CbGpPWpGaD
Lapatinib—Rash—Bleomycin—testicular cancer	0.000334	0.00128	CcSEcCtD
Lapatinib—Dermatitis—Bleomycin—testicular cancer	0.000334	0.00128	CcSEcCtD
Lapatinib—Hypersensitivity—Ifosfamide—testicular cancer	0.000334	0.00128	CcSEcCtD
Lapatinib—Alanine aminotransferase increased—Doxorubicin—testicular cancer	0.000333	0.00127	CcSEcCtD
Lapatinib—EGFR—Downstream signaling events of B Cell Receptor (BCR)—KITLG—testicular cancer	0.000332	0.0022	CbGpPWpGaD
Lapatinib—ERBB2—Signaling by NGF—FGFR3—testicular cancer	0.000332	0.0022	CbGpPWpGaD
Lapatinib—Neutropenia—Epirubicin—testicular cancer	0.00033	0.00126	CcSEcCtD
Lapatinib—EGFR—Role of LAT2/NTAL/LAB on calcium mobilization—KIT—testicular cancer	0.000328	0.00218	CbGpPWpGaD
Lapatinib—Stomatitis—Methotrexate—testicular cancer	0.000328	0.00125	CcSEcCtD
Lapatinib—ERBB4—Signaling by NGF—FGFR3—testicular cancer	0.000327	0.00217	CbGpPWpGaD
Lapatinib—ABCB1—lymph node—testicular cancer	0.000326	0.00297	CbGeAlD
Lapatinib—ERBB2—Signaling Pathways—INSL3—testicular cancer	0.000326	0.00216	CbGpPWpGaD
Lapatinib—Asthenia—Ifosfamide—testicular cancer	0.000325	0.00124	CcSEcCtD
Lapatinib—CYP3A5—Biological oxidations—HPGDS—testicular cancer	0.000322	0.00214	CbGpPWpGaD
Lapatinib—EGFR—Integrated Pancreatic Cancer Pathway—STK11—testicular cancer	0.000322	0.00213	CbGpPWpGaD
Lapatinib—Pruritus—Ifosfamide—testicular cancer	0.000321	0.00123	CcSEcCtD
Lapatinib—ERBB4—Signaling Pathways—INSL3—testicular cancer	0.000321	0.00213	CbGpPWpGaD
Lapatinib—Dyspnoea—Etoposide—testicular cancer	0.000319	0.00122	CcSEcCtD
Lapatinib—Hepatobiliary disease—Methotrexate—testicular cancer	0.000318	0.00122	CcSEcCtD
Lapatinib—Epistaxis—Methotrexate—testicular cancer	0.000317	0.00121	CcSEcCtD
Lapatinib—EGFR—DAP12 interactions—KITLG—testicular cancer	0.000317	0.0021	CbGpPWpGaD
Lapatinib—EGFR—Signaling by FGFR in disease—KITLG—testicular cancer	0.000317	0.0021	CbGpPWpGaD
Lapatinib—EGFR—Fc epsilon receptor (FCERI) signaling—KITLG—testicular cancer	0.000317	0.0021	CbGpPWpGaD
Lapatinib—Pneumonia—Epirubicin—testicular cancer	0.000316	0.00121	CcSEcCtD
Lapatinib—Nausea—Bleomycin—testicular cancer	0.000315	0.0012	CcSEcCtD
Lapatinib—Infestation—Epirubicin—testicular cancer	0.000315	0.0012	CcSEcCtD
Lapatinib—Infestation NOS—Epirubicin—testicular cancer	0.000315	0.0012	CcSEcCtD
Lapatinib—Vomiting—Dactinomycin—testicular cancer	0.000314	0.0012	CcSEcCtD
Lapatinib—EGFR—Signaling by EGFR—KITLG—testicular cancer	0.000314	0.00208	CbGpPWpGaD
Lapatinib—Rash—Dactinomycin—testicular cancer	0.000312	0.00119	CcSEcCtD
Lapatinib—Decreased appetite—Etoposide—testicular cancer	0.000311	0.00119	CcSEcCtD
Lapatinib—EGFR—Signaling by EGFR in Cancer—KITLG—testicular cancer	0.000311	0.00206	CbGpPWpGaD
Lapatinib—Diarrhoea—Ifosfamide—testicular cancer	0.00031	0.00119	CcSEcCtD
Lapatinib—EGFR—Signaling by PDGF—KITLG—testicular cancer	0.00031	0.00205	CbGpPWpGaD
Lapatinib—Gastrointestinal disorder—Etoposide—testicular cancer	0.000309	0.00118	CcSEcCtD
Lapatinib—Fatigue—Etoposide—testicular cancer	0.000309	0.00118	CcSEcCtD
Lapatinib—Neuropathy peripheral—Epirubicin—testicular cancer	0.000308	0.00118	CcSEcCtD
Lapatinib—Stomatitis—Epirubicin—testicular cancer	0.000307	0.00117	CcSEcCtD
Lapatinib—Constipation—Etoposide—testicular cancer	0.000306	0.00117	CcSEcCtD
Lapatinib—Neutropenia—Doxorubicin—testicular cancer	0.000305	0.00117	CcSEcCtD
Lapatinib—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—KIT—testicular cancer	0.000305	0.00202	CbGpPWpGaD
Lapatinib—ERBB2—Signaling by NGF—KIT—testicular cancer	0.000305	0.00202	CbGpPWpGaD
Lapatinib—PIK3C2B—Metabolism—STK11—testicular cancer	0.000304	0.00202	CbGpPWpGaD
Lapatinib—ERBB4—Signaling by NGF—KIT—testicular cancer	0.0003	0.00199	CbGpPWpGaD
Lapatinib—Hepatobiliary disease—Epirubicin—testicular cancer	0.000298	0.00114	CcSEcCtD
Lapatinib—Epistaxis—Epirubicin—testicular cancer	0.000297	0.00113	CcSEcCtD
Lapatinib—PI4KB—Metabolism—STK11—testicular cancer	0.000294	0.00195	CbGpPWpGaD
Lapatinib—Nausea—Dactinomycin—testicular cancer	0.000294	0.00112	CcSEcCtD
Lapatinib—TAP1—Immune System—FGFR3—testicular cancer	0.000293	0.00194	CbGpPWpGaD
Lapatinib—EGFR—B Cell Activation—KITLG—testicular cancer	0.000293	0.00194	CbGpPWpGaD
Lapatinib—Pneumonia—Doxorubicin—testicular cancer	0.000293	0.00112	CcSEcCtD
Lapatinib—Gastrointestinal pain—Etoposide—testicular cancer	0.000293	0.00112	CcSEcCtD
Lapatinib—Infestation NOS—Doxorubicin—testicular cancer	0.000291	0.00111	CcSEcCtD
Lapatinib—Infestation—Doxorubicin—testicular cancer	0.000291	0.00111	CcSEcCtD
Lapatinib—Vomiting—Ifosfamide—testicular cancer	0.000288	0.0011	CcSEcCtD
Lapatinib—Hypersensitivity—Cisplatin—testicular cancer	0.000288	0.0011	CcSEcCtD
Lapatinib—Rash—Ifosfamide—testicular cancer	0.000286	0.00109	CcSEcCtD
Lapatinib—Dermatitis—Ifosfamide—testicular cancer	0.000285	0.00109	CcSEcCtD
Lapatinib—Neuropathy peripheral—Doxorubicin—testicular cancer	0.000285	0.00109	CcSEcCtD
Lapatinib—Stomatitis—Doxorubicin—testicular cancer	0.000284	0.00109	CcSEcCtD
Lapatinib—Abdominal pain—Etoposide—testicular cancer	0.000283	0.00108	CcSEcCtD
Lapatinib—EGFR—Signaling by SCF-KIT—FGFR3—testicular cancer	0.000282	0.00187	CbGpPWpGaD
Lapatinib—EGFR—NGF signalling via TRKA from the plasma membrane—KITLG—testicular cancer	0.000281	0.00186	CbGpPWpGaD
Lapatinib—Asthenia—Cisplatin—testicular cancer	0.00028	0.00107	CcSEcCtD
Lapatinib—Cardiac disorder—Methotrexate—testicular cancer	0.00028	0.00107	CcSEcCtD
Lapatinib—CYP2C8—Biological oxidations—HPGDS—testicular cancer	0.000279	0.00185	CbGpPWpGaD
Lapatinib—Connective tissue disorder—Epirubicin—testicular cancer	0.000278	0.00106	CcSEcCtD
Lapatinib—Hepatobiliary disease—Doxorubicin—testicular cancer	0.000275	0.00105	CcSEcCtD
Lapatinib—Epistaxis—Doxorubicin—testicular cancer	0.000275	0.00105	CcSEcCtD
Lapatinib—Angiopathy—Methotrexate—testicular cancer	0.000274	0.00105	CcSEcCtD
Lapatinib—Immune system disorder—Methotrexate—testicular cancer	0.000273	0.00104	CcSEcCtD
Lapatinib—Mediastinal disorder—Methotrexate—testicular cancer	0.000272	0.00104	CcSEcCtD
Lapatinib—EGFR—Regulation of Actin Cytoskeleton—FGFR3—testicular cancer	0.00027	0.00179	CbGpPWpGaD
Lapatinib—EGFR—Downstream signaling of activated FGFR—FGFR3—testicular cancer	0.00027	0.00179	CbGpPWpGaD
Lapatinib—TAP1—Immune System—KIT—testicular cancer	0.000269	0.00178	CbGpPWpGaD
Lapatinib—Nausea—Ifosfamide—testicular cancer	0.000269	0.00103	CcSEcCtD
Lapatinib—Diarrhoea—Cisplatin—testicular cancer	0.000267	0.00102	CcSEcCtD
Lapatinib—Alopecia—Methotrexate—testicular cancer	0.000267	0.00102	CcSEcCtD
Lapatinib—EGFR—Signaling by GPCR—INSL3—testicular cancer	0.000266	0.00177	CbGpPWpGaD
Lapatinib—EGFR—Signaling by ERBB4—FGFR3—testicular cancer	0.000266	0.00176	CbGpPWpGaD
Lapatinib—Mental disorder—Methotrexate—testicular cancer	0.000264	0.00101	CcSEcCtD
Lapatinib—Hypersensitivity—Etoposide—testicular cancer	0.000264	0.00101	CcSEcCtD
Lapatinib—Malnutrition—Methotrexate—testicular cancer	0.000263	0.001	CcSEcCtD
Lapatinib—Cardiac disorder—Epirubicin—testicular cancer	0.000262	0.001	CcSEcCtD
Lapatinib—EGFR—Signaling by SCF-KIT—KIT—testicular cancer	0.000259	0.00172	CbGpPWpGaD
Lapatinib—Asthenia—Etoposide—testicular cancer	0.000257	0.000982	CcSEcCtD
Lapatinib—Connective tissue disorder—Doxorubicin—testicular cancer	0.000257	0.000982	CcSEcCtD
Lapatinib—Angiopathy—Epirubicin—testicular cancer	0.000256	0.00098	CcSEcCtD
Lapatinib—Immune system disorder—Epirubicin—testicular cancer	0.000255	0.000976	CcSEcCtD
Lapatinib—ERBB2—Innate Immune System—KITLG—testicular cancer	0.000255	0.00169	CbGpPWpGaD
Lapatinib—Mediastinal disorder—Epirubicin—testicular cancer	0.000255	0.000973	CcSEcCtD
Lapatinib—Back pain—Methotrexate—testicular cancer	0.000254	0.000972	CcSEcCtD
Lapatinib—EGFR—Downstream signal transduction—FGFR3—testicular cancer	0.000254	0.00168	CbGpPWpGaD
Lapatinib—Pruritus—Etoposide—testicular cancer	0.000253	0.000969	CcSEcCtD
Lapatinib—EGFR—Signaling by FGFR—FGFR3—testicular cancer	0.000253	0.00167	CbGpPWpGaD
Lapatinib—EGFR—Signaling by ERBB2—FGFR3—testicular cancer	0.000251	0.00167	CbGpPWpGaD
Lapatinib—ERBB4—Innate Immune System—KITLG—testicular cancer	0.000251	0.00166	CbGpPWpGaD
Lapatinib—EGFR—DAP12 signaling—FGFR3—testicular cancer	0.00025	0.00166	CbGpPWpGaD
Lapatinib—Alopecia—Epirubicin—testicular cancer	0.00025	0.000954	CcSEcCtD
Lapatinib—CYP2C19—Biological oxidations—HPGDS—testicular cancer	0.000249	0.00165	CbGpPWpGaD
Lapatinib—Vomiting—Cisplatin—testicular cancer	0.000248	0.00095	CcSEcCtD
Lapatinib—EGFR—Downstream signaling of activated FGFR—KIT—testicular cancer	0.000248	0.00164	CbGpPWpGaD
Lapatinib—Mental disorder—Epirubicin—testicular cancer	0.000247	0.000946	CcSEcCtD
Lapatinib—EGFR—Downstream signaling events of B Cell Receptor (BCR)—FGFR3—testicular cancer	0.000247	0.00163	CbGpPWpGaD
Lapatinib—Rash—Cisplatin—testicular cancer	0.000246	0.000942	CcSEcCtD
Lapatinib—Dermatitis—Cisplatin—testicular cancer	0.000246	0.000941	CcSEcCtD
Lapatinib—ERBB2—Immune System—BCL10—testicular cancer	0.000246	0.00163	CbGpPWpGaD
Lapatinib—Malnutrition—Epirubicin—testicular cancer	0.000246	0.00094	CcSEcCtD
Lapatinib—Diarrhoea—Etoposide—testicular cancer	0.000245	0.000937	CcSEcCtD
Lapatinib—ABCB1—Transmembrane transport of small molecules—SLC2A6—testicular cancer	0.000245	0.00162	CbGpPWpGaD
Lapatinib—ERBB2—Adaptive Immune System—KITLG—testicular cancer	0.000244	0.00162	CbGpPWpGaD
Lapatinib—ERBB2—Axon guidance—MMP2—testicular cancer	0.000244	0.00162	CbGpPWpGaD
Lapatinib—EGFR—Signaling by ERBB4—KIT—testicular cancer	0.000244	0.00162	CbGpPWpGaD
Lapatinib—Anaemia—Methotrexate—testicular cancer	0.000243	0.000929	CcSEcCtD
Lapatinib—Cardiac disorder—Doxorubicin—testicular cancer	0.000243	0.000928	CcSEcCtD
Lapatinib—ERBB4—Immune System—BCL10—testicular cancer	0.000242	0.00161	CbGpPWpGaD
Lapatinib—ERBB4—Adaptive Immune System—KITLG—testicular cancer	0.000241	0.0016	CbGpPWpGaD
Lapatinib—Back pain—Epirubicin—testicular cancer	0.000238	0.00091	CcSEcCtD
Lapatinib—Angiopathy—Doxorubicin—testicular cancer	0.000237	0.000907	CcSEcCtD
Lapatinib—Immune system disorder—Doxorubicin—testicular cancer	0.000236	0.000903	CcSEcCtD
Lapatinib—Mediastinal disorder—Doxorubicin—testicular cancer	0.000236	0.000901	CcSEcCtD
Lapatinib—EGFR—DAP12 interactions—FGFR3—testicular cancer	0.000235	0.00156	CbGpPWpGaD
Lapatinib—EGFR—Signaling by FGFR in disease—FGFR3—testicular cancer	0.000235	0.00156	CbGpPWpGaD
Lapatinib—EGFR—Fc epsilon receptor (FCERI) signaling—FGFR3—testicular cancer	0.000235	0.00156	CbGpPWpGaD
Lapatinib—Leukopenia—Methotrexate—testicular cancer	0.000235	0.000899	CcSEcCtD
Lapatinib—EGFR—Signaling by EGFR—FGFR3—testicular cancer	0.000233	0.00155	CbGpPWpGaD
Lapatinib—EGFR—Downstream signal transduction—KIT—testicular cancer	0.000233	0.00155	CbGpPWpGaD
Lapatinib—Nausea—Cisplatin—testicular cancer	0.000232	0.000888	CcSEcCtD
Lapatinib—EGFR—Signaling by FGFR—KIT—testicular cancer	0.000232	0.00154	CbGpPWpGaD
Lapatinib—EGFR—Signaling by EGFR in Cancer—FGFR3—testicular cancer	0.000231	0.00153	CbGpPWpGaD
Lapatinib—EGFR—Direct p53 effectors—MMP2—testicular cancer	0.000231	0.00153	CbGpPWpGaD
Lapatinib—Alopecia—Doxorubicin—testicular cancer	0.000231	0.000883	CcSEcCtD
Lapatinib—EGFR—Signaling by ERBB2—KIT—testicular cancer	0.000231	0.00153	CbGpPWpGaD
Lapatinib—EGFR—Signaling by PDGF—FGFR3—testicular cancer	0.00023	0.00153	CbGpPWpGaD
Lapatinib—EGFR—DAP12 signaling—KIT—testicular cancer	0.00023	0.00152	CbGpPWpGaD
Lapatinib—Cough—Methotrexate—testicular cancer	0.000229	0.000877	CcSEcCtD
Lapatinib—Mental disorder—Doxorubicin—testicular cancer	0.000229	0.000876	CcSEcCtD
Lapatinib—Vomiting—Etoposide—testicular cancer	0.000228	0.00087	CcSEcCtD
Lapatinib—Malnutrition—Doxorubicin—testicular cancer	0.000227	0.00087	CcSEcCtD
Lapatinib—Anaemia—Epirubicin—testicular cancer	0.000227	0.000869	CcSEcCtD
Lapatinib—EGFR—Downstream signaling events of B Cell Receptor (BCR)—KIT—testicular cancer	0.000226	0.0015	CbGpPWpGaD
Lapatinib—Rash—Etoposide—testicular cancer	0.000226	0.000863	CcSEcCtD
Lapatinib—Dermatitis—Etoposide—testicular cancer	0.000225	0.000862	CcSEcCtD
Lapatinib—Headache—Etoposide—testicular cancer	0.000224	0.000858	CcSEcCtD
Lapatinib—ABCB1—Integrated Pancreatic Cancer Pathway—HPGDS—testicular cancer	0.000224	0.00148	CbGpPWpGaD
Lapatinib—Arthralgia—Methotrexate—testicular cancer	0.000224	0.000855	CcSEcCtD
Lapatinib—Myalgia—Methotrexate—testicular cancer	0.000224	0.000855	CcSEcCtD
Lapatinib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—testicular cancer	0.000222	0.000849	CcSEcCtD
Lapatinib—Leukopenia—Epirubicin—testicular cancer	0.00022	0.000842	CcSEcCtD
Lapatinib—Back pain—Doxorubicin—testicular cancer	0.00022	0.000842	CcSEcCtD
Lapatinib—EGFR—B Cell Activation—FGFR3—testicular cancer	0.000218	0.00144	CbGpPWpGaD
Lapatinib—Palpitations—Epirubicin—testicular cancer	0.000217	0.000831	CcSEcCtD
Lapatinib—EGFR—Fc epsilon receptor (FCERI) signaling—KIT—testicular cancer	0.000216	0.00143	CbGpPWpGaD
Lapatinib—EGFR—Signaling by FGFR in disease—KIT—testicular cancer	0.000216	0.00143	CbGpPWpGaD
Lapatinib—EGFR—DAP12 interactions—KIT—testicular cancer	0.000216	0.00143	CbGpPWpGaD
Lapatinib—EGFR—Signaling by NGF—KITLG—testicular cancer	0.000216	0.00143	CbGpPWpGaD
Lapatinib—Cough—Epirubicin—testicular cancer	0.000215	0.00082	CcSEcCtD
Lapatinib—Anaphylactic shock—Methotrexate—testicular cancer	0.000214	0.00082	CcSEcCtD
Lapatinib—EGFR—Signaling by EGFR—KIT—testicular cancer	0.000214	0.00142	CbGpPWpGaD
Lapatinib—Infection—Methotrexate—testicular cancer	0.000213	0.000815	CcSEcCtD
Lapatinib—Nausea—Etoposide—testicular cancer	0.000213	0.000813	CcSEcCtD
Lapatinib—EGFR—Signaling by EGFR in Cancer—KIT—testicular cancer	0.000212	0.00141	CbGpPWpGaD
Lapatinib—EGFR—Signaling by PDGF—KIT—testicular cancer	0.000211	0.0014	CbGpPWpGaD
Lapatinib—Nervous system disorder—Methotrexate—testicular cancer	0.00021	0.000804	CcSEcCtD
Lapatinib—Anaemia—Doxorubicin—testicular cancer	0.00021	0.000804	CcSEcCtD
Lapatinib—Myalgia—Epirubicin—testicular cancer	0.000209	0.0008	CcSEcCtD
Lapatinib—Arthralgia—Epirubicin—testicular cancer	0.000209	0.0008	CcSEcCtD
Lapatinib—EGFR—NGF signalling via TRKA from the plasma membrane—FGFR3—testicular cancer	0.000208	0.00138	CbGpPWpGaD
Lapatinib—Skin disorder—Methotrexate—testicular cancer	0.000208	0.000796	CcSEcCtD
Lapatinib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—testicular cancer	0.000208	0.000795	CcSEcCtD
Lapatinib—Anorexia—Methotrexate—testicular cancer	0.000204	0.000782	CcSEcCtD
Lapatinib—EGFR—Innate Immune System—BCL10—testicular cancer	0.000204	0.00135	CbGpPWpGaD
Lapatinib—Leukopenia—Doxorubicin—testicular cancer	0.000204	0.000779	CcSEcCtD
Lapatinib—Palpitations—Doxorubicin—testicular cancer	0.000201	0.000769	CcSEcCtD
Lapatinib—Anaphylactic shock—Epirubicin—testicular cancer	0.000201	0.000767	CcSEcCtD
Lapatinib—EGFR—B Cell Activation—KIT—testicular cancer	0.0002	0.00133	CbGpPWpGaD
Lapatinib—Infection—Epirubicin—testicular cancer	0.000199	0.000762	CcSEcCtD
Lapatinib—Cough—Doxorubicin—testicular cancer	0.000199	0.000759	CcSEcCtD
Lapatinib—Nervous system disorder—Epirubicin—testicular cancer	0.000197	0.000753	CcSEcCtD
Lapatinib—EGFR—Adaptive Immune System—BCL10—testicular cancer	0.000196	0.0013	CbGpPWpGaD
Lapatinib—Musculoskeletal discomfort—Methotrexate—testicular cancer	0.000195	0.000747	CcSEcCtD
Lapatinib—Skin disorder—Epirubicin—testicular cancer	0.000195	0.000745	CcSEcCtD
Lapatinib—Insomnia—Methotrexate—testicular cancer	0.000194	0.000742	CcSEcCtD
Lapatinib—Arthralgia—Doxorubicin—testicular cancer	0.000194	0.000741	CcSEcCtD
Lapatinib—Myalgia—Doxorubicin—testicular cancer	0.000194	0.000741	CcSEcCtD
Lapatinib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—testicular cancer	0.000192	0.000736	CcSEcCtD
Lapatinib—EGFR—NGF signalling via TRKA from the plasma membrane—KIT—testicular cancer	0.000191	0.00127	CbGpPWpGaD
Lapatinib—Anorexia—Epirubicin—testicular cancer	0.000191	0.000731	CcSEcCtD
Lapatinib—Dyspnoea—Methotrexate—testicular cancer	0.000191	0.000731	CcSEcCtD
Lapatinib—ERBB2—Innate Immune System—FGFR3—testicular cancer	0.000189	0.00125	CbGpPWpGaD
Lapatinib—Dyspepsia—Methotrexate—testicular cancer	0.000189	0.000722	CcSEcCtD
Lapatinib—Decreased appetite—Methotrexate—testicular cancer	0.000186	0.000713	CcSEcCtD
Lapatinib—ERBB4—Innate Immune System—FGFR3—testicular cancer	0.000186	0.00124	CbGpPWpGaD
Lapatinib—Anaphylactic shock—Doxorubicin—testicular cancer	0.000186	0.00071	CcSEcCtD
Lapatinib—Gastrointestinal disorder—Methotrexate—testicular cancer	0.000185	0.000708	CcSEcCtD
Lapatinib—Fatigue—Methotrexate—testicular cancer	0.000185	0.000707	CcSEcCtD
Lapatinib—Infection—Doxorubicin—testicular cancer	0.000184	0.000705	CcSEcCtD
Lapatinib—Musculoskeletal discomfort—Epirubicin—testicular cancer	0.000183	0.000699	CcSEcCtD
Lapatinib—Nervous system disorder—Doxorubicin—testicular cancer	0.000182	0.000696	CcSEcCtD
Lapatinib—ERBB2—Adaptive Immune System—FGFR3—testicular cancer	0.000182	0.0012	CbGpPWpGaD
Lapatinib—Insomnia—Epirubicin—testicular cancer	0.000181	0.000694	CcSEcCtD
Lapatinib—Skin disorder—Doxorubicin—testicular cancer	0.00018	0.00069	CcSEcCtD
Lapatinib—ERBB4—Adaptive Immune System—FGFR3—testicular cancer	0.000179	0.00119	CbGpPWpGaD
Lapatinib—Dyspnoea—Epirubicin—testicular cancer	0.000179	0.000684	CcSEcCtD
Lapatinib—Anorexia—Doxorubicin—testicular cancer	0.000177	0.000677	CcSEcCtD
Lapatinib—Dyspepsia—Epirubicin—testicular cancer	0.000177	0.000675	CcSEcCtD
Lapatinib—Gastrointestinal pain—Methotrexate—testicular cancer	0.000175	0.000671	CcSEcCtD
Lapatinib—Decreased appetite—Epirubicin—testicular cancer	0.000174	0.000667	CcSEcCtD
Lapatinib—ERBB2—Developmental Biology—MMP2—testicular cancer	0.000174	0.00116	CbGpPWpGaD
Lapatinib—ERBB2—Innate Immune System—KIT—testicular cancer	0.000174	0.00115	CbGpPWpGaD
Lapatinib—Gastrointestinal disorder—Epirubicin—testicular cancer	0.000173	0.000663	CcSEcCtD
Lapatinib—Fatigue—Epirubicin—testicular cancer	0.000173	0.000662	CcSEcCtD
Lapatinib—Constipation—Epirubicin—testicular cancer	0.000172	0.000656	CcSEcCtD
Lapatinib—ERBB4—Innate Immune System—KIT—testicular cancer	0.000171	0.00113	CbGpPWpGaD
Lapatinib—Abdominal pain—Methotrexate—testicular cancer	0.000169	0.000648	CcSEcCtD
Lapatinib—Musculoskeletal discomfort—Doxorubicin—testicular cancer	0.000169	0.000647	CcSEcCtD
Lapatinib—Insomnia—Doxorubicin—testicular cancer	0.000168	0.000642	CcSEcCtD
Lapatinib—ERBB2—Adaptive Immune System—KIT—testicular cancer	0.000167	0.00111	CbGpPWpGaD
Lapatinib—Dyspnoea—Doxorubicin—testicular cancer	0.000166	0.000633	CcSEcCtD
Lapatinib—ERBB4—Adaptive Immune System—KIT—testicular cancer	0.000164	0.00109	CbGpPWpGaD
Lapatinib—Gastrointestinal pain—Epirubicin—testicular cancer	0.000164	0.000628	CcSEcCtD
Lapatinib—Dyspepsia—Doxorubicin—testicular cancer	0.000163	0.000625	CcSEcCtD
Lapatinib—ABCB1—Integrated Pancreatic Cancer Pathway—STK11—testicular cancer	0.000163	0.00108	CbGpPWpGaD
Lapatinib—Decreased appetite—Doxorubicin—testicular cancer	0.000161	0.000617	CcSEcCtD
Lapatinib—EGFR—Signaling by NGF—FGFR3—testicular cancer	0.00016	0.00106	CbGpPWpGaD
Lapatinib—Gastrointestinal disorder—Doxorubicin—testicular cancer	0.00016	0.000613	CcSEcCtD
Lapatinib—Fatigue—Doxorubicin—testicular cancer	0.00016	0.000612	CcSEcCtD
Lapatinib—Constipation—Doxorubicin—testicular cancer	0.000159	0.000607	CcSEcCtD
Lapatinib—Abdominal pain—Epirubicin—testicular cancer	0.000159	0.000607	CcSEcCtD
Lapatinib—Hypersensitivity—Methotrexate—testicular cancer	0.000158	0.000604	CcSEcCtD
Lapatinib—EGFR—Signaling Pathways—INSL3—testicular cancer	0.000157	0.00104	CbGpPWpGaD
Lapatinib—Asthenia—Methotrexate—testicular cancer	0.000154	0.000588	CcSEcCtD
Lapatinib—Gastrointestinal pain—Doxorubicin—testicular cancer	0.000152	0.000581	CcSEcCtD
Lapatinib—Pruritus—Methotrexate—testicular cancer	0.000152	0.00058	CcSEcCtD
Lapatinib—CYP3A4—Biological oxidations—HPGDS—testicular cancer	0.00015	0.000993	CbGpPWpGaD
Lapatinib—ERBB2—Disease—H2AFZ—testicular cancer	0.000149	0.000986	CbGpPWpGaD
Lapatinib—ERBB2—Immune System—KITLG—testicular cancer	0.000148	0.000983	CbGpPWpGaD
Lapatinib—Hypersensitivity—Epirubicin—testicular cancer	0.000148	0.000565	CcSEcCtD
Lapatinib—EGFR—Signaling by NGF—KIT—testicular cancer	0.000147	0.000976	CbGpPWpGaD
Lapatinib—Abdominal pain—Doxorubicin—testicular cancer	0.000147	0.000561	CcSEcCtD
Lapatinib—Diarrhoea—Methotrexate—testicular cancer	0.000147	0.000561	CcSEcCtD
Lapatinib—ERBB4—Disease—H2AFZ—testicular cancer	0.000147	0.000971	CbGpPWpGaD
Lapatinib—ERBB4—Immune System—KITLG—testicular cancer	0.000146	0.000968	CbGpPWpGaD
Lapatinib—Asthenia—Epirubicin—testicular cancer	0.000144	0.000551	CcSEcCtD
Lapatinib—Pruritus—Epirubicin—testicular cancer	0.000142	0.000543	CcSEcCtD
Lapatinib—Diarrhoea—Epirubicin—testicular cancer	0.000137	0.000525	CcSEcCtD
Lapatinib—ERBB2—Disease—KITLG—testicular cancer	0.000137	0.000907	CbGpPWpGaD
Lapatinib—Hypersensitivity—Doxorubicin—testicular cancer	0.000137	0.000523	CcSEcCtD
Lapatinib—Vomiting—Methotrexate—testicular cancer	0.000136	0.000521	CcSEcCtD
Lapatinib—Rash—Methotrexate—testicular cancer	0.000135	0.000517	CcSEcCtD
Lapatinib—Dermatitis—Methotrexate—testicular cancer	0.000135	0.000517	CcSEcCtD
Lapatinib—ERBB4—Disease—KITLG—testicular cancer	0.000135	0.000894	CbGpPWpGaD
Lapatinib—Headache—Methotrexate—testicular cancer	0.000134	0.000514	CcSEcCtD
Lapatinib—Asthenia—Doxorubicin—testicular cancer	0.000133	0.000509	CcSEcCtD
Lapatinib—Pruritus—Doxorubicin—testicular cancer	0.000131	0.000502	CcSEcCtD
Lapatinib—Vomiting—Epirubicin—testicular cancer	0.000128	0.000488	CcSEcCtD
Lapatinib—Nausea—Methotrexate—testicular cancer	0.000127	0.000487	CcSEcCtD
Lapatinib—Diarrhoea—Doxorubicin—testicular cancer	0.000127	0.000486	CcSEcCtD
Lapatinib—Rash—Epirubicin—testicular cancer	0.000127	0.000484	CcSEcCtD
Lapatinib—Dermatitis—Epirubicin—testicular cancer	0.000126	0.000483	CcSEcCtD
Lapatinib—Headache—Epirubicin—testicular cancer	0.000126	0.000481	CcSEcCtD
Lapatinib—EGFR—Innate Immune System—KITLG—testicular cancer	0.000123	0.000816	CbGpPWpGaD
Lapatinib—Nausea—Epirubicin—testicular cancer	0.000119	0.000456	CcSEcCtD
Lapatinib—EGFR—Immune System—BCL10—testicular cancer	0.000119	0.000788	CbGpPWpGaD
Lapatinib—EGFR—Adaptive Immune System—KITLG—testicular cancer	0.000118	0.000783	CbGpPWpGaD
Lapatinib—EGFR—Axon guidance—MMP2—testicular cancer	0.000118	0.000782	CbGpPWpGaD
Lapatinib—Vomiting—Doxorubicin—testicular cancer	0.000118	0.000451	CcSEcCtD
Lapatinib—Rash—Doxorubicin—testicular cancer	0.000117	0.000448	CcSEcCtD
Lapatinib—Dermatitis—Doxorubicin—testicular cancer	0.000117	0.000447	CcSEcCtD
Lapatinib—Headache—Doxorubicin—testicular cancer	0.000116	0.000445	CcSEcCtD
Lapatinib—Nausea—Doxorubicin—testicular cancer	0.00011	0.000422	CcSEcCtD
Lapatinib—ERBB2—Immune System—FGFR3—testicular cancer	0.00011	0.00073	CbGpPWpGaD
Lapatinib—ERBB4—Immune System—FGFR3—testicular cancer	0.000109	0.000719	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism of lipids and lipoproteins—HPGDS—testicular cancer	0.000107	0.000711	CbGpPWpGaD
Lapatinib—ERBB2—Signaling Pathways—H2AFZ—testicular cancer	0.000104	0.000691	CbGpPWpGaD
Lapatinib—ERBB2—Signaling Pathways—STK11—testicular cancer	0.000104	0.000687	CbGpPWpGaD
Lapatinib—ERBB4—Signaling Pathways—H2AFZ—testicular cancer	0.000103	0.00068	CbGpPWpGaD
Lapatinib—ERBB4—Signaling Pathways—STK11—testicular cancer	0.000102	0.000676	CbGpPWpGaD
Lapatinib—ERBB2—Disease—FGFR3—testicular cancer	0.000102	0.000674	CbGpPWpGaD
Lapatinib—ERBB2—Immune System—KIT—testicular cancer	0.000101	0.00067	CbGpPWpGaD
Lapatinib—ERBB4—Disease—FGFR3—testicular cancer	0.0001	0.000664	CbGpPWpGaD
Lapatinib—ERBB4—Immune System—KIT—testicular cancer	9.96e-05	0.00066	CbGpPWpGaD
Lapatinib—ERBB2—Signaling Pathways—KITLG—testicular cancer	9.59e-05	0.000635	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism of lipids and lipoproteins—HPGDS—testicular cancer	9.57e-05	0.000634	CbGpPWpGaD
Lapatinib—ERBB4—Signaling Pathways—KITLG—testicular cancer	9.44e-05	0.000626	CbGpPWpGaD
Lapatinib—ERBB2—Disease—KIT—testicular cancer	9.34e-05	0.000619	CbGpPWpGaD
Lapatinib—ERBB4—Disease—KIT—testicular cancer	9.2e-05	0.00061	CbGpPWpGaD
Lapatinib—EGFR—Innate Immune System—FGFR3—testicular cancer	9.15e-05	0.000606	CbGpPWpGaD
Lapatinib—EGFR—Adaptive Immune System—FGFR3—testicular cancer	8.78e-05	0.000582	CbGpPWpGaD
Lapatinib—EGFR—Developmental Biology—MMP2—testicular cancer	8.43e-05	0.000558	CbGpPWpGaD
Lapatinib—EGFR—Innate Immune System—KIT—testicular cancer	8.4e-05	0.000557	CbGpPWpGaD
Lapatinib—EGFR—Adaptive Immune System—KIT—testicular cancer	8.06e-05	0.000534	CbGpPWpGaD
Lapatinib—EGFR—Disease—H2AFZ—testicular cancer	7.19e-05	0.000477	CbGpPWpGaD
Lapatinib—EGFR—Immune System—KITLG—testicular cancer	7.17e-05	0.000475	CbGpPWpGaD
Lapatinib—ERBB2—Signaling Pathways—FGFR3—testicular cancer	7.12e-05	0.000472	CbGpPWpGaD
Lapatinib—ERBB4—Signaling Pathways—FGFR3—testicular cancer	7.02e-05	0.000465	CbGpPWpGaD
Lapatinib—EGFR—Disease—KITLG—testicular cancer	6.62e-05	0.000439	CbGpPWpGaD
Lapatinib—ERBB2—Signaling Pathways—KIT—testicular cancer	6.54e-05	0.000433	CbGpPWpGaD
Lapatinib—ERBB4—Signaling Pathways—KIT—testicular cancer	6.44e-05	0.000427	CbGpPWpGaD
Lapatinib—CYP3A5—Metabolism—HPGDS—testicular cancer	5.51e-05	0.000365	CbGpPWpGaD
Lapatinib—EGFR—Immune System—FGFR3—testicular cancer	5.33e-05	0.000353	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—H2AFZ—testicular cancer	5.04e-05	0.000334	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—STK11—testicular cancer	5.01e-05	0.000332	CbGpPWpGaD
Lapatinib—EGFR—Disease—FGFR3—testicular cancer	4.92e-05	0.000326	CbGpPWpGaD
Lapatinib—EGFR—Immune System—KIT—testicular cancer	4.89e-05	0.000324	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism—HPGDS—testicular cancer	4.78e-05	0.000317	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—KITLG—testicular cancer	4.63e-05	0.000307	CbGpPWpGaD
Lapatinib—EGFR—Disease—KIT—testicular cancer	4.52e-05	0.000299	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism—HPGDS—testicular cancer	4.26e-05	0.000283	CbGpPWpGaD
Lapatinib—ABCB1—Metabolism—HPGDS—testicular cancer	4.16e-05	0.000276	CbGpPWpGaD
Lapatinib—CYP3A5—Metabolism—STK11—testicular cancer	4.01e-05	0.000266	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism—STK11—testicular cancer	3.47e-05	0.00023	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—FGFR3—testicular cancer	3.44e-05	0.000228	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—KIT—testicular cancer	3.16e-05	0.00021	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism—STK11—testicular cancer	3.1e-05	0.000205	CbGpPWpGaD
Lapatinib—ABCB1—Metabolism—STK11—testicular cancer	3.02e-05	0.0002	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—HPGDS—testicular cancer	2.56e-05	0.00017	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—STK11—testicular cancer	1.86e-05	0.000123	CbGpPWpGaD
